Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 5;36(1):31–42. doi: 10.3892/or.2016.4786

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Seo et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Effect of the STAT3 inhibitor S3I-201 on the growth of BT-474 cells. (A) BT-474 cells were treated with different doses of the STAT3 inhibitor S3I-201 (0–500 µM). After 72 h, the cell viability was assessed using a cell proliferation assay. (B) BT-474 cells were treated with different doses of the STAT3 inhibitor S3I-201 (0-500 µM). The relative cell growth rate was measured by MTT assay after 24, 48 and 72 h. The growth rate of the vehicle-treated cells was set to 100%, and the relative decrease in cell viability resulting from the S3I-201 treatment was expressed as a percentage of the control. Data are shown as the means of three independent experiments (error bars denote SD). ^***P<0.001. (C) BT-474 cells were treated with the STAT3 inhibitor S3I-201 for 24 h. Whole cell lysates were analyzed by western blotting with anti-p-STAT3, anti-STAT3, anti-VEGF and anti-tubulin antibodies. The data shown are representative of three independent experiments that gave similar results.

Effect of the STAT3 inhibitor S3I-201 on the growth of BT-474 cells. (A) BT-474 cells were treated with different doses of the STAT3 inhibitor S3I-201 (0–500 µM). After 72 h, the cell viability was assessed using a cell proliferation assay. (B) BT-474 cells were treated with different doses of the STAT3 inhibitor S3I-201 (0-500 µM). The relative cell growth rate was measured by MTT assay after 24, 48 and 72 h. The growth rate of the vehicle-treated cells was set to 100%, and the relative decrease in cell viability resulting from the S3I-201 treatment was expressed as a percentage of the control. Data are shown as the means of three independent experiments (error bars denote SD). ^***P<0.001. (C) BT-474 cells were treated with the STAT3 inhibitor S3I-201 for 24 h. Whole cell lysates were analyzed by western blotting with anti-p-STAT3, anti-STAT3, anti-VEGF and anti-tubulin antibodies. The data shown are representative of three independent experiments that gave similar results.